Shattuck Labs, Inc. (STTK) NASDAQ

1.25

+0.02(+1.63%)

Updated at February 05 04:00PM

Currency In USD

Shattuck Labs, Inc.

Address

500 West 5th Street

Austin, TX 78703

United States of America

Phone

512 900 4690

Sector

Healthcare

Industry

Biotechnology

Employees

75

First IPO Date

October 09, 2020

Key Executives

NameTitlePayYear Born
Dr. Taylor H. Schreiber M.D., Ph.D.Co-Founder, Chief Executive Officer & Director792,8851980
Ms. Casi DeYoungChief Business Officer523,4821971
Dr. Abhinav A. Shukla Ph.D.Chief Technical Officer567,3981973
Mr. Andrew R. Neill M.B.A.Chief Financial Officer603,9561986
Dr. Arunthathy Nirmalini Pandite M.B.A., M.D.Chief Medical Officer695,2431959
Dr. Stephen Stout J.D., Ph.D.General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer01975
Mr. George Fromm Ph.D.Co-Chief Scientific Officer0N/A
Mr. Conor Richardson CPAVice President of Investor Relations0N/A
Dr. Thomas Lampkin Pharm.D.Senior Vice President of Regulatory Affairs0N/A
Mr. Suresh de Silva Ph.D.Co-Chief Scientific Officer0N/A

Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.